ArticleFrontiers in pharmacology2022
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03289949 (The Neurobiological Effect of 5-HT2AR Modulation), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Neurobiological Effect of 5-HT2AR Modulation
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Pooled it
- Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.Translational psychiatry · 2025Pooled it
- Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.Psychopharmacology · 2025Pooled it
- Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.Scientific reports · 2025Trial
- Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.Clinical pharmacology and therapeutics · 2025Trial
- Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.Translational psychiatry · 2024Trial
- LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.The British journal of psychiatry : the journal of mental science · 2024Trial
- Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.Journal of psychopharmacology (Oxford, England) · 2026Article
- Psilocybin modulates social behaviour in male and female mice in a time-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psilocybin's effect on human brain synaptic plasticity.Translational psychiatry · 2026Article
- The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.Journal of psychopharmacology (Oxford, England) · 2026Review
- Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy.Nature communications · 2026Article
- Psychedelic-Assisted Interventions in Palliative Care: A Narrative Overview and Critical Evaluation.Healthcare (Basel, Switzerland) · 2026Review
- High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.Journal of psychopharmacology (Oxford, England) · 2026Article
- Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework.Frontiers in psychiatry · 2026Article
- Reappraising the claims of evolutionary continuity between thanatosis and near-death experiences.Brain communications · 2026Article
- Development and psychometric evaluation of the Oneness Experience Scale.Frontiers in psychology · 2026Article
- Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study (NCT03289949), 35 medium-high doses of psilocybin were administered to 28 healthy volunteers (12 females). By the end of the dosing day, participants reported the intensity of their acute experience using the 30-item Mystical Experience Questionnaire (MEQ) and an open-form qualitative report from home. Persisting psychological effects attributed to the psilocybin experience were measured using the Persisting Effects Questionnaire (PEQ) 3-months after administration. Using a linear latent-variable model we show that the MEQ total score is positively associated with the later emergence of positive PEQ effects (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.